Pharmion — Merger or Acquisition (February 2008)
27 slides from Pharmion's merger presentation, Feb 20, 2008
Slide 1: Proposed Acquisition of Pharmion Corporation by Celgene Corporation
Proposed Acquisition of Pharmion Corporation by Celgene Corporation February 2008
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, perform
Slide 3: Overview of Proposed Acquisition
Overview of Proposed Acquisition Celgene to Acquire Pharmion for Approximately $2.9 Billion, or $72/share Definitive merger agreement signed, announced 11/18/2007 PHRM shareholders to receive $25/share in cash and $47/share in shares of CELG stock upon closing of transaction Exchange ratio fixed whe
Slide 4: Stockholder Proposals
Stockholder Proposals Proposal No. 1 - Approval of the Merger The acquisition of Pharmion by Celgene Proposal No. 2 - Approval of possible adjournment of the special meeting of Pharmion stockholders Provides for the adjournment of the special meeting if there are not sufficient votes at the time of
Slide 5: Pharmion Overview
Pharmion Overview Global biopharmaceutical company founded in 2000; IPO completed in 2003 Acquires, develops and commercializes hematology and oncology products Established development, regulatory, and commercial organizations in the US, EU and Australia Distributor network in place for key ROW mark
Slide 6: Pharmion Background
Pharmion Background Licensed rights to Thalidomide (from CELG) and Vidaza in 2001 Launched compassionate use of Thalidomide in second- line multiple myeloma in 2003 Vidaza approved and launched in the U.S. for the treatment of MDS in 2004 Licensed or acquired rights to Satraplatin, MGCD0103 and Amru
Slide 7: Pharmion Background
Pharmion Background Completed EU submission for Thalidomide in first-line multiple myeloma in 2007 Announced strong Vidaza overall survival results from Phase 3 study in higher-risk MDS patients in 2007 Received EMEA recommendation for approval for Thalidomide in first-line multiple myeloma in 2008
Slide 8: Stock Price History
Stock Price History BTK: +56.5% PHRM vs. BTK Since 11/6/03 (PHRM IPO) PHRM: +400.9%
Slide 9: Stock Price History
Stock Price History PHRM: $70.12 PHRM Since 11/6/03 (PHRM IPO)
Slide 10: Stock Price History
Stock Price History PHRM Since 1/1/07 PHRM: $70.12
Slide 11: Pharmion Product Portfolio
Pharmion Product Portfolio Phase 2 Phase 3 Marketed Compassionate use sales - EU Pre-clinical Phase 1 US Under EU review* * Failed to show overall survival advantage in Phase 3 study w/ Vidaza in lymphoma 1st line SCLC +/- cisplatin (EORTC) MGCD0103 Vidaza MDS AML Solid tumors Oral Azacitidine MDS /
Slide 12: Vidaza Overview
Vidaza Overview Approved in U.S. in 2004 for all MDS subtypes based on disease response rate data. First drug approved for the treatment of MDS Orphan drug exclusivity expires May 2011 Two additional therapies approved for treatment of MDS in 2006 Revlimid for treatment of subset of lower risk MDS p
Slide 13: Vidaza Overview
Vidaza Overview Topline survival results from Vidaza Phase 3 MDS study comparing Vidaza to conventional care regimens (CCR) released in 2007 Overall survival increased by 74% Two year survival rate of 50.8% vs. 26.2% for CCR 9.4 months median survival benefit (24.4 mos. vs 15 mos.) First drug to dem
Slide 14: Thalidomide Overview
Thalidomide Overview Received positive opinion for treatment of first-line multiple myeloma from European Medicines Agency Based on study results demonstrating survival advantage of 18.4 months when added to standard therapy Ratification by European Commission anticipated within two to three months
Slide 15: Key Upcoming 2008 Milestones
Key Upcoming 2008 Milestones EU approval and launch of Thalidomide for the treatment of first-line multiple myeloma Dacogen top-line overall survival data for the treatment of higher-risk MDS patients EMEA decision for Vidaza in the treatment of higher-risk MDS patients Expansion of U.S. label for V
Slide 16: Celgene Overview
Celgene Overview Fully integrated international biopharmaceutical company founded in 1986; IPO completed in 1987 Discovers, develops and commercializes hematology, oncology and inflammation products Established operations, including commercial, clinical and regulatory, in over 50-countries, includin
Slide 17: Pharmion's Rationale for the Merger
Pharmion's Rationale for the Merger Consideration offered represents significant premium over PHRM's current and historical stock prices Supported by fairness opinion from PHRM's financial advisor, Banc of America Merger with CELG makes unique strategic sense, enabling PHRM stockholders to participa
Slide 18: Merger Consideration Offered
Merger Consideration Offered merger consideration value of $72/share represents premium significantly above PHRM historical trading prices: 46.1 percent over closing price of $49.28 on last trading date before PHRM board of directors meeting* 72.6 percent over 90-day average closing price prior to m
Slide 19: Transaction Valuation
Transaction Valuation Celgene's offer of $72.00 per share represents an attractive value for PHRM, based upon multiple valuation methodologies Analysis was conducted upon PHRM management's best and current view of the stand-alone financial projections
Slide 20: Premiums Paid in Biotech
Premiums Paid in Biotech Celgene's offer to PHRM represents an attractive premium relative to precedent biotechnology transactions 1 Day prior 3 Months prior Source: Public company filings, press releases, FactSet and Thomson. 1 Week prior 1 Month prior
Slide 21: Risk Diversification
Risk Diversification Since its IPO, PHRM stock price has been very volatile and largely dependent on the clinical, regulatory and commercial results of one or two of its products and/or their competitors PHRM management and Board of Directors believed this concentration of business risk would contin
Slide 22: PHRM Stockholders Receive Significant Value Through Merger
PHRM Stockholders Receive Significant Value Through Merger Proceeds Merger consideration results in greater value to PHRM stockholders than pursuing management's current business plan Uncertainty associated with achieving management's projections and unpredictability of PHRM's operating results goin
Slide 23: Merger Process
Merger Process PHRM Board of Directors elected not to conduct "auction process" prior to signing merger agreement with CELG Successfully negotiated with CELG to increase offer price to $72/share from $57/share - represents a 26 percent increase PHRM's Board unanimously approved the deal and determin
Slide 24: Celgene's Rationale for the Merger
Celgene's Rationale for the Merger Acquisition of PHRM will enable CELG to enhance its portfolio of therapies for patients with life-threatening illnesses worldwide Adds PHRM's four marketed products and several in development to CELG pipeline for hematologic and solid tumor cancers Extends CELG's s
Slide 25: Celgene's Rationale for the Merger
Celgene's Rationale for the Merger Ability to leverage existing infrastructure to market PHRM's approved products Strong fit in hematology Deep understanding of multiple myeloma and MDS markets Significant operational and financial synergies Expands reach in MDS and MM therapeutic categories Vidaza'
Slide 26: Market Reaction to Transaction
Market Reaction to Transaction Sapna Srivastava - Morgan Stanley: "A very good deal for Pharmion." "The potential acquisition is probably the best way for Pharmion to realize value." (11/19/07) Yaron Werber - Citi: "A Good Deal At a Fair Price" (11/19/07) Will Ho - Bank of America: "We view the term
Slide 27: Additional Information about the Merger and Where to Find It
Additional Information about the Merger and Where to Find It Additional Information about the Merger and Where to Find It This presentation shall not constitute an offer of any securities for sale. The acquisition will be submitted to Pharmion's stockholders for their consideration. In connection wi